These signaling pathways have been reported to be co-activated or have cross-talked with EGFR in HCC and other tumor types (Al Zobair et al., 2013; Berasain and Avila, 2014; Hoang et al., 2017; Zhu et al., 2017), and could consequently promote tumorigenesis. Here, EGFR is linked to hepatocellular carcinoma.